|
1
|
Orsolini L, Pompili S and Volpe U:
Schizophrenia: A narrative review of etiopathogenetic, diagnostic
and treatment aspects. J Clin Med. 11:50402022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McGrath J, Saha S, Chant D and Welham J:
Schizophrenia: A concise overview of incidence, prevalence, and
mortality. Epidemiol Rev. 30:67–76. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brink M, Green A, Bojesen AB, Lamberti JS,
Conwell Y and Andersen K: Excess medical comorbidity and mortality
across the lifespan in schizophrenia. Schizophr Res. 206:347–354.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Penninx BWJH and Lange SMM: Metabolic
syndrome in psychiatric patients: Overview, mechanisms, and
implications. Dialogues Clin Neurosci. 20:63–73. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nielsen RE, Banner J and Jensen SE:
Cardiovascular disease in patients with severe mental illness. Nat
Rev Cardiol. 18:136–145. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Correll CU, Solmi M, Croatto G, Schneider
LK, Rohani-Montez SC, Fairley L, Smith N, Bitter I, Gorwood P,
Taipale H and Tiihonen J: Mortality in people with schizophrenia: A
systematic review and meta-analysis of relative risk and
aggravating or attenuating factors. World Psychiatry. 21:248–271.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tzur Bitan D, Krieger I, Berkovitch A,
Comaneshter D and Cohen A: Chronic kidney disease in adults with
schizophrenia: A nationwide population-based study. Gen Hosp
Psychiatry. 58:1–6. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hsu YH, Cheng JS, Ouyang WC, Lin CL, Huang
CT and Hsu CC: Lower incidence of end-stage renal disease but
suboptimal pre-dialysis renal care in Schizophrenia: A 14-year
nationwide cohort study. PLoS One. 10:e01405102015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kazlauskienė L, Butnorienė J and Norkus A:
Metabolic syndrome related to cardiovascular events in a 10-year
prospective study. Diabetol Metab Syndr. 7:1022015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Grundy SM, Cleeman JI, Daniels SR, Donato
KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith
SC Jr, et al: Diagnosis and management of the metabolic syndrome:
An American Heart Association/National Heart, Lung, and Blood
Institute Scientific Statement. Circulation. 112:2735–2752. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Saklayen MG: The global epidemic of the
metabolic syndrome. Curr Hypertens Rep. 20:122018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vancampfort D, Stubbs B, Mitchell AJ, De
Hert M, Wampers M, Ward PB, Rosenbaum S and Correll CU: Risk of
metabolic syndrome and its components in people with schizophrenia
and related psychotic disorders, bipolar disorder and major
depressive disorder: A systematic review and meta-analysis. World
Psychiatry. 14:339–347. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Salari N, Maghami N, Ammari T, Mosafer H,
Abdullahi R, Rasoulpoor S, Babajani F, Mahmodzadeh B and Mohammadi
M: Global prevalence of metabolic syndrome in Schizophrenia
patients: A systematic review and meta-analysis. J Prev (2022).
45:973–986. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vancampfort D, Wampers M, Mitchell AJ,
Correll CU, De Herdt A, Probst M and De Hert M: A meta-analysis of
cardio-metabolic abnormalities in drug naïve, first-episode and
multi-episode patients with schizophrenia versus general population
controls. World Psychiatry. 12:240–250. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sugai T, Suzuki Y, Yamazaki M, Shimoda K,
Mori T, Ozeki Y, Matsuda H, Sugawara N, Yasui-Furukori N, Minami Y,
et al: High prevalence of obesity, hypertension, hyperlipidemia,
and diabetes mellitus in japanese outpatients with Schizophrenia: A
nationwide survey. PLoS One. 11:e01664292016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Carney R, Cotter J, Bradshaw T, Firth J
and Yung AR: Cardiometabolic risk factors in young people at
ultra-high risk for psychosis: A systematic review and
meta-analysis. Schizophr Res. 170:290–300. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Emul M and Kalelioglu T: Etiology of
cardiovascular disease in patients with schizophrenia: Current
perspectives. Neuropsychiatr Dis Treat. 11:2493–2503. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rouillon F and Sorbara F: Schizophrenia
and diabetes: Epidemiological data. Eur Psychiatry. 20 (Suppl
4):S345–S348. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Suvisaari J, Keinänen J, Eskelinen S and
Mantere O: Diabetes and Schizophrenia. Curr Diab Rep. 16:162016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Peet M: Diet, diabetes and Schizophrenia:
Review and hypothesis. Br J Psychiatry. (Suppl 184):S102–S105.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pillinger T, Beck K, Gobjila C, Donocik
JG, Jauhar S and Howes OD: Impaired glucose homeostasis in
first-episode Schizophrenia: A systematic review and meta-analysis.
JAMA Psychiatry. 74:261–269. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bora E, Akdede BB and Alptekin K: The
relationship between cognitive impairment in Schizophrenia and
metabolic syndrome: A systematic review and meta-analysis. Psychol
Med. 47:1030–1040. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Grover S, R P, Sahoo S, Gopal S, Nehra R,
Ganesh A, Raghavan V and Sankaranarayan A: Relationship of
metabolic syndrome and neurocognitive deficits in patients with
Schizophrenia. Psychiatry Res. 278:56–64. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bosia M, Buonocore M, Bechi M, Santarelli
L, Spangaro M, Cocchi F, Guglielmino C, Bianchi L, Bringheli S,
Bosinelli F and Cavallaro R: Improving cognition to increase
treatment efficacy in Schizophrenia: Effects of metabolic syndrome
on cognitive remediation's outcome. Front Psychiatry. 9:6472018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lindenmayer JP, Khan A, Kaushik S, Thanju
A, Praveen R, Hoffman L, Cherath L, Valdez G and Wance D:
Relationship between metabolic syndrome and cognition in patients
with schizophrenia. Schizophr Res. 142:171–176. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mizuki Y, Sakamoto S, Okahisa Y, Yada Y,
Hashimoto N, Takaki M and Yamada N: Mechanisms underlying the
comorbidity of schizophrenia and type 2 diabetes mellitus. Int J
Neuropsychopharmacol. 24:367–382. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kalejahi P, Kheirouri S, Noorazar SG and
Sanayei M: The relationship between brain-derived neurotrophic
factor and metabolic syndrome in patients with chronic
schizophrenia: A systematic review. Neuropeptides. 87:1021352021.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rojo LE, Gaspar PA, Silva H, Risco L,
Arena P, Cubillos-Robles K and Jara B: Metabolic syndrome and
obesity among users of second generation antipsychotics: A global
challenge for modern psychopharmacology. Pharmacol Res. 101:74–85.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Henderson DC, Vincenzi B, Andrea NV, Ulloa
M and Copeland PM: Pathophysiological mechanisms of increased
cardiometabolic risk in people with schizophrenia and other severe
mental illnesses. Lancet Psychiatry. 2:452–464. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Goldsmith DR, Rapaport MH and Miller BJ: A
meta-analysis of blood cytokine network alterations in psychiatric
patients: Comparisons between schizophrenia, bipolar disorder and
depression. Mol Psychiatry. 21:1696–1709. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Flatow J, Buckley P and Miller BJ:
Meta-analysis of oxidative stress in Schizophrenia. Biol
Psychiatry. 74:400–409. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Perry BI, Burgess S, Jones HJ, Zammit S,
Upthegrove R, Mason AM, Day FR, Langenberg C, Wareham NJ, Jones PB
and Khandaker GM: The potential shared role of inflammation in
insulin resistance and schizophrenia: A bidirectional two-sample
mendelian randomization study. PLoS Med. 18:e10034552021.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dasgupta A, Singh OP, Rout JK, Saha T and
Mandal S: Insulin resistance and metabolic profile in antipsychotic
naïve schizophrenia patients. Prog Neuropsychopharmacol Biol
Psychiatry. 34:1202–1207. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen S, Broqueres-You D, Yang G, Wang Z,
Li Y, Wang N, Zhang X, Yang F and Tan Y: Relationship between
insulin resistance, dyslipidaemia and positive symptom in Chinese
antipsychotic-naive first-episode patients with schizophrenia.
Psychiatry Res. 210:825–829. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao Z, Ksiezak-Reding H, Riggio S,
Haroutunian V and Pasinetti GM: Insulin receptor deficits in
schizophrenia and in cellular and animal models of insulin receptor
dysfunction. Schizophr Res. 84:1–14. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Saxena A, Patel D, Ayesha IE, Monson NR,
Klair N, Patel U and Khan S: Metabolic syndrome causing cognitive
impairment in patients with Schizophrenia: A systematic review.
Cureus. 15:e475872023.PubMed/NCBI
|
|
37
|
Baothman OA, Zamzami MA, Taher I, Abubaker
J and Abu-Farha M: The role of Gut Microbiota in the development of
obesity and Diabetes. Lipids Health Dis. 15:1082016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Müller N: Inflammation in Schizophrenia:
Pathogenetic aspects and therapeutic considerations. Schizophr
Bull. 44:973–982. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cryan JF, O'Riordan KJ, Cowan CSM, Sandhu
KV, Bastiaanssen TFS, Boehme M, Codagnone MG, Cussotto S, Fulling
C, Golubeva AV, et al: The microbiota-gut-brain axis. Physiol Rev.
99:1877–2013. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
He Y, Kosciolek T, Tang J, Zhou Y, Li Z,
Ma X, Zhu Q, Yuan N, Yuan L, Li C, et al: Gut microbiome and
magnetic resonance spectroscopy study of subjects at ultra-high
risk for psychosis may support the membrane hypothesis. Eur
Psychiatry. 53:37–45. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Misiak B, Łoniewski I, Marlicz W, Frydecka
D, Szulc A, Rudzki L and Samochowiec J: The HPA axis dysregulation
in severe mental illness: Can we shift the blame to gut microbiota?
Prog Neuropsychopharmacol Biol Psychiatry. 102:1099512020.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ferentinos P, Rizos E, Douzenis A,
Papadopoulou A, Christodoulou C, Peppa M and Lykouras L: Androgen
insensitivity and liability to drug-induced extrapyramidal
Symptoms. Gend Med. 8:156–160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tsigkaropoulou E, Peppa M, Zompola C,
Rizos E, Xelioti I, Chatziioannou S, Filippopoulou A and Lykouras
L: Hypogonadism due to hyperprolactinemia and subsequent first
episode of psychosis. Gend Med. 9:56–60. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bellivier F: Schizophrenia, antipsychotics
and diabetes: Genetic aspects. Eur Psychiatry. 20 (Suppl
4):S335–S339. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ayalew M, Le-Niculescu H, Levey DF, Jain
N, Changala B, Patel SD, Winiger E, Breier A, Shekhar A, Amdur R,
et al: Convergent functional genomics of schizophrenia: from
comprehensive understanding to genetic risk prediction. Mol
Psychiatry. 17:887–905. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Fujihara K: Beyond the γ-aminobutyric acid
hypothesis of schizophrenia. Front Cell Neurosci. 17:11616082023.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Molina JD, Avila S, Rubio G and
López-Muñoz F: Metabolomic Connections between Schizophrenia,
antipsychotic drugs and metabolic Syndrome: A variety of players.
Curr Pharm Des. 27:4049–4061. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Castillo RI, Rojo LE, Henriquez-Henriquez
M, Silva H, Maturana A, Villar MJ, Fuentes M and Gaspar PA: From
molecules to the clinic: Linking Schizophrenia and metabolic
syndrome through sphingolipids metabolism. Front Neurosci.
10:4882016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tsubomoto M, Kawabata R, Zhu X, Minabe Y,
Chen K, Lewis DA and Hashimoto T: Expression of transcripts
selective for GABA neuron subpopulations across the Cortical
visuospatial working memory network in the healthy state and
Schizophrenia. Cereb Cortex. 29:3540–3550. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Fish KN, Rocco BR, Wilson JD and Lewis DA:
Laminar-Specific alterations in calbindin-positive boutons in the
prefrontal cortex of subjects with Schizophrenia. Biol Psychiatry.
94:142–152. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Curley AA, Arion D, Volk DW, Asafu-Adjei
JK, Sampson AR, Fish KN and Lewis DA: Cortical deficits of glutamic
acid decarboxylase 67 expression in Schizophrenia: Clinical,
protein, and cell type-specific features. Am J Psychiatry.
168:921–929. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Uematsu M, Hirai Y, Karube F, Ebihara S,
Kato M, Abe K, Obata K, Yoshida S, Hirabayashi M, Yanagawa Y and
Kawaguchi Y: Quantitative chemical composition of cortical
GABAergic neurons revealed in transgenic venus-expressing rats.
Cereb Cortex. 18:315–330. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Dienel SJ, Dowling KF, Barile Z, Bazmi HH,
Liu A, Vespoli JC, Fish KN and Lewis DA: Diagnostic specificity and
association with cognition of molecular alterations in prefrontal
somatostatin neurons in Schizophrenia. JAMA Psychiatry.
80:1235–1245. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Scheper M, Sørensen FNF, Ruffolo G, Gaeta
A, Lissner LJ, Anink JJ, Korshunova I, Jansen FE, Riney K, van
Hecke W, et al: Impaired GABAergic regulation and developmental
immaturity in interneurons derived from the medial ganglionic
eminence in the tuberous sclerosis complex. Acta Neuropathol.
147:802024. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Rasband MN and Macklin WB: Myelin
Structure and Biochemistry. Basic Neurochemistry. Elsevier; pp.
180–199. 2012, View Article : Google Scholar
|
|
56
|
Valdés-Tovar M, Rodríguez-Ramírez AM,
Rodríguez-Cárdenas L, Sotelo-Ramírez CE, Camarena B,
Sanabrais-Jiménez MA, Solís-Chagoyán H, Argueta J and
López-Riquelme GO: Insights into myelin dysfunction in
schizophrenia and bipolar disorder. World J Psychiatry. 12:264–285.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Takahashi N, Sakurai T, Davis KL and
Buxbaum JD: Linking oligodendrocyte and myelin dysfunction to
neurocircuitry abnormalities in schizophrenia. Prog Neurobiol.
93:13–24. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Boiko AS, Mednova IA, Kornetova EG, Semke
AV, Bokhan NA and Ivanova SA: Cell adhesion molecules in
Schizophrenia patients with metabolic syndrome. Metabolites.
13:3762023. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Varden Gjerde K, Bartz-Johannessen C,
Steen VM, Andreassen OA, Steen NE, Ueland T, Lekva T, Rettenbacher
M, Joa I, Reitan SK, et al: Cellular adhesion molecules in
drug-naïve and previously medicated patients with
schizophrenia-spectrum disorders. Schizophr Res. 267:223–229. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Sheikh MA, O'Connell KS, Lekva T, Szabo A,
Akkouh IA, Osete JR, Agartz I, Engh JA, Andreou D, Boye B, et al:
Systemic cell adhesion molecules in severe mental Illness:
Potential role of intercellular CAM-1 in linking peripheral and
neuroinflammation. Biol Psychiatry. 93:187–196. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Vidal PP and Sans A: Vestibular System.
The Rat Nervous System. Elsevier; pp. 965–996. 2004, View Article : Google Scholar
|
|
62
|
Brisch R, Saniotis A, Wolf R, Bielau H,
Bernstein HG, Steiner J, Bogerts B, Braun K, Jankowski Z,
Kumaratilake J, Henneberg M and Gos T: The role of dopamine in
Schizophrenia from a neurobiological and evolutionary perspective:
Old fashioned, but still in vogue. Front Psychiatry. 5:472014.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Blaess S, Stott SRW and Ang SL: The
generation of midbrain dopaminergic neurons. Patterning and Cell
Type Specification in the Developing CNS and PNS. Elsevier; pp.
369–398. 2020, View Article : Google Scholar
|
|
64
|
Gragnoli C, Reeves GM, Reazer J and
Postolache TT: Dopamine-prolactin pathway potentially contributes
to the schizophrenia and type 2 diabetes comorbidity. Transl
Psychiatry. 6:e7852016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Goh KK, Chen CYA, Wu TH, Chen CH and Lu
ML: Crosstalk between Schizophrenia and metabolic Syndrome: The
role of oxytocinergic dysfunction. Int J Mol Sci. 23:70922022.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Yu H, Yan H, Li J, Li Z, Zhang X, Ma Y,
Mei L, Liu C, Cai L, Wang Q, et al: Common variants on 2p16.1,
6p22.1 and 10q24.32 are associated with schizophrenia in Han
Chinese population. Mol Psychiatry. 22:954–960. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zhang P, Bian Y, Liu N, Tang Y, Pan C, Hu
Y and Tang Z: The SNP rs1625579 in miR-137 gene and risk of
schizophrenia in Chinese population: A meta-analysis. Compr
Psychiatry. 67:26–32. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Boiko AS, Pozhidaev IV, Paderina DZ,
Mednova IA, Goncharova AA, Fedorenko OY, Kornetova EG, Semke AV,
Bokhan NA, Loonen AJM and Ivanova SA: Gene polymorphisms of
hormonal regulators of metabolism in patients with Schizophrenia
with metabolic syndrome. Genes (Basel). 13:8442022. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Brandl EJ, Frydrychowicz C, Tiwari AK,
Lett TA, Kitzrow W, Büttner S, Ehrlich S, Meltzer HY, Lieberman JA,
Kennedy JL, et al: Association study of polymorphisms in leptin and
leptin receptor genes with antipsychotic-induced body weight gain.
Prog Neuropsychopharmacol Biol Psychiatry. 38:134–141. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Mulder H, Franke B, van der-Beek van der
AA, Arends J, Wilmink FW, Scheffer H and Egberts AC: The
association between HTR2C gene polymorphisms and the metabolic
syndrome in patients with Schizophrenia. J Clin Psychopharmacol.
27:338–343. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Chen J, Wu J, Mize T, Shui D and Chen X:
Prediction of Schizophrenia diagnosis by integration of genetically
correlated conditions and traits. J Neuroimmune Pharmacol.
13:532–540. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Chen Y, Wang Y, Fang X, Zhang Y, Song L
and Zhang C: Association of the HTR2C-759C/T polymorphism and
antipsychotic-induced weight gain: A meta-analysis. Gen Psychiatr.
33:e1001922020. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Sicard MN, Zai CC, Tiwari AK, Souza RP,
Meltzer HY, Lieberman JA, Kennedy JL and Müller DJ: Polymorphisms
of the HTR2C gene and antipsychotic-induced weight gain: An update
and meta-analysis. Pharmacogenomics. 11:1561–1571. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Brummett BH, Babyak MA, Singh A, Hauser
ER, Jiang R, Huffman KM, Kraus WE, Shah SH, Siegler IC and Williams
RB: Lack of association of a functional polymorphism in the
serotonin receptor gene with body mass index and depressive
symptoms in a large meta-analysis of population based studies.
Front Genet. 9:4232018. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Sneller MH, de Boer N, Everaars S,
Schuurmans M, Guloksuz S, Cahn W and Luykx JJ: Clinical,
biochemical and genetic variables associated with metabolic
syndrome in patients with Schizophrenia spectrum disorders using
second-generation antipsychotics: A systematic review. Front
Psychiatry. 12:6259352021. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Shams TA and Müller DJ: Antipsychotic
induced weight gain: Genetics, epigenetics, and biomarkers
reviewed. Curr Psychiatry Rep. 16:4732014. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Wallace TJ, Zai CC, Brandl EJ and Müller
DJ: Role of 5-HT(2C) receptor gene variants in
antipsychotic-induced weight gain. Pharmgenomics Pers Med. 4:83–93.
2011.PubMed/NCBI
|
|
78
|
Bah J, Westberg L, Baghaei F, Henningsson
S, Rosmond R, Melke J, Holm G and Eriksson E: Further exploration
of the possible influence of polymorphisms in HTR2C and 5HTT on
body weight. Metabolism. 59:1156–1163. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Klerk M, Verhoef P, Clarke R, Blom HJ, Kok
FJ and Schouten EG; MTHFR Studies Collaboration Group, : MTHFR
677C→T polymorphism and risk of coronary heart disease: A mata
analysis. JAMA. 288:2023–2031. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Lu ML, Ku WC, Syifa N, Hu SC, Chou CT, Wu
YH, Kuo PH, Chen CH, Chen WJ and Wu TH: Developing a sensitive
platform to measure 5-methyltetrahydrofolate in subjects with MTHFR
and PON1 gene polymorphisms. Nutrients. 14:33202022. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
van Winkel R, Rutten BP, Peerbooms O,
Peuskens J, van Os J and De Hert M: MTHFR and risk of metabolic
syndrome in patients with Schizophrenia. Schizophr Res.
121:193–198. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Roffeei SN, Reynolds GP, Zainal NZ, Said
MA, Hatim A, Aida SA and Mohamed Z: Association of ADRA2A and MTHFR
gene polymorphisms with weight loss following antipsychotic
switching to aripiprazole or ziprasidone. Hum Psychopharmacol.
29:38–45. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Roffeei SN, Mohamed Z, Reynolds GP, Said
MA, Hatim A, Mohamed EH, Aida SA and Zainal NZ: Association of FTO,
LEPR and MTHFR gene polymorphisms with metabolic syndrome in
Schizophrenia patients receiving antipsychotics. Pharmacogenomics.
15:477–485. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Bathina S and Das UN: Brain-derived
neurotrophic factor and its clinical implications. Arch Med Sci.
6:1164–1178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Priya I, Sharma S, Sharma I, Mahajan R and
Kapoor N: A review of potential candidate genes polymorphism
responsible for schiz-ophrenia risk. Int J Sci Res Biol Sci.
5:186–195. 2019.
|
|
86
|
Ping J, Zhang J, Wan J, Huang C, Luo J, Du
B and Jiang T: A polymorphism in the BDNF Gene (rs11030101) is
associated with negative symptoms in Chinese Han patients with
Schizophrenia. Front Genet. 13:8492272022. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Fu X, Wang J, Du J, Sun J, Baranova A and
Zhang F: BDNF Gene's Role in Schizophrenia: From risk allele to
methylation implications. Front Psychiatry. 11:5642772020.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Vajagathali M and Ramakrishnan V: Genetic
predisposition of BDNF (rs6265) gene is susceptible to
Schizophrenia: A prospective study and updated meta-analysis.
Neurología (Engl Ed). 39:361–371. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Ehrhart F, Silva A, Amelsvoort TV, von
Scheibler E, Evelo C and Linden DEJ: Copy number variant risk loci
for schizophrenia converge on the BDNF pathway. World J Biol
Psychiatry. 25:222–232. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Bednarova A, Habalova V, Krivosova M,
Marcatili M and Tkac I: Association study of BDNF, SLC6A4, and FTO
genetic variants with Schizophrenia spectrum disorders. J Pers Med.
13:6582023. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Czerwensky F, Leucht S and Steimer W:
Association of the common MC4R rs17782313 polymorphism with
antipsychotic-related weight gain. J Clin Psychopharmacol.
33:74–79. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Heald A, Pendlebury J, Anderson S, Narayan
V, Guy M, Gibson M, Haddad P and Livingston M: Lifestyle factors
and the metabolic syndrome in Schizophrenia: A cross-sectional
study. Ann Gen Psychiatry. 16:122017. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Dipasquale S, Pariante CM, Dazzan P,
Aguglia E, McGuire P and Mondelli V: The dietary pattern of
patients with schizophrenia: A systematic review. J Psychiatr Res.
47:197–207. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Amani R: Is dietary pattern of
schizophrenia patients different from healthy subjects? BMC
Psychiatry. 7:152007. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Aucoin M, LaChance L, Cooley K and Kidd S:
Diet and psychosis: A scoping review. Neuropsychobiology. 79:20–42.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Kelly C and McCreadie R: Cigarette smoking
and schizophrenia. Adv Psychiatr Treat. 6:327–331. 2000. View Article : Google Scholar
|
|
97
|
Myles N, Newall HD, Curtis J, Nielssen O,
Shiers D and Large M: Tobacco use before, at, and after
first-episode psychosis: A systematic meta-analysis. J Clin
Psychiatry. 73:468–475. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Breese CR, Lee MJ, Adams CE, Sullivan B,
Logel J, Gillen KM, Marks MJ, Collins AC and Leonard S: Abnormal
regulation of high affinity nicotinic receptors in subjects with
Schizophrenia. Neuropsychopharmacology. 23:351–364. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Koskinen J, Löhönen J, Koponen H, Isohanni
M and Miettunen J: Prevalence of alcohol use disorders in
schizophrenia-a systematic review and meta-analysis. Acta Psychiatr
Scand. 120:85–96. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Fatma F, Baati I, Omri S, Sallemi R and
Masmoudi J: Medication adherence in schizophrenia. Eur Psychiatry.
33:S586. 2016. View Article : Google Scholar
|
|
101
|
Novick D, Haro JM, Suarez D, Perez V,
Dittmann RW and Haddad PM: Predictors and clinical consequences of
non-adherence with antipsychotic medication in the outpatient
treatment of schizophrenia. Psychiatry Res. 176:109–113. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Mitchell AJ, Vancampfort D, De Herdt A, Yu
W and De Hert M: Is the prevalence of metabolic syndrome and
metabolic abnormalities increased in early Schizophrenia? A
comparative meta-analysis of first episode, untreated and treated
patients. Schizophr Bull. 39:295–305. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Szmulewicz AG, Angriman F, Pedroso FE,
Vazquez C and Martino DJ: Long-Term antipsychotic use and major
cardiovascular events: A Retrospective Cohort Study. J Clin
Psychiatry. 78:e905–e912. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Foley DL and Morley KI: Systematic review
of early cardiometabolic outcomes of the first treated episode of
psychosis. Arch Gen Psychiatry. 68:609–616. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Templeman LA, Reynolds GP, Arranz B and
San L: Polymorphisms of the 5-HT2C receptor and leptin genes are
associated with antipsychotic drug-induced weight gain in Caucasian
subjects with a first-episode psychosis. Pharmacogenet Genomics.
15:195–200. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Zhang ZJ, Yao ZJ, Liu W, Fang Q and
Reynolds GP: Effects of antipsychotics on fat deposition and
changes in leptin and insulin levels. Br J Psychiatry. 184:58–62.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Faulkner G, Cohn T, Remington G and Irving
H: Body mass index, waist circumference and quality of life in
individuals with schizophrenia☆. Schizophr Res. 90:174–178. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Lester H, Marshall M, Jones P, Fowler D,
Amos T, Khan N and Birchwood M: Views of young people in early
intervention services for first-episode psychosis in England.
Psychiatr Serv. 62:882–887. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Weiden PJ, Mackell JA and McDonnell DD:
Obesity as a risk factor for antipsychotic noncompliance. Schizophr
Res. 66:51–57. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Chang SC, Goh KK and Lu ML: Metabolic
disturbances associated with antipsychotic drug treatment in
patients with schizophrenia: State-of-the-art and future
perspectives. World J Psychiatry. 11:696–710. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Leucht S, Cipriani A, Spineli L, Mavridis
D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, et
al: Comparative efficacy and tolerability of 15 antipsychotic drugs
in schizophrenia: A multiple-treatments meta-analysis. Lancet.
382:951–962. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Cooper SJ, Reynolds GP; With expert
co-authors (in alphabetical order), ; Barnes T, England E, Haddad
PM, Heald A, Holt R, Lingford-Hughes A, Osborn D, et al: BAP
guidelines on the management of weight gain, metabolic disturbances
and cardiovascular risk associated with psychosis and antipsychotic
drug treatment. J Psychopharmacol. 30:717–748. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Fonseka TM, Müller DJ and Kennedy SH:
Inflammatory cytokines and antipsychotic-induced weight gain:
Review and clinical implications. Mol Neuropsychiatry. 2:1–14.
2016.PubMed/NCBI
|
|
114
|
Newcomer JW: Antipsychotic medications:
Metabolic and cardiovascular risk. J Clin Psychiatry. 68 (Suppl
4):8–13. 2007.PubMed/NCBI
|
|
115
|
Newcomer JW: Second-generation (atypical)
antipsychotics and metabolic effects: A comprehensive literature
review. CNS Drugs. 19 (Suppl 1):S1–S93. 2005. View Article : Google Scholar
|
|
116
|
Ballon JS, Pajvani U, Freyberg Z, Leibel
RL and Lieberman JA: Molecular pathophysiology of metabolic effects
of antipsychotic medications. Trends Endocrinol Metab. 25:593–600.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Carli M, Kolachalam S, Longoni B, Pintaudi
A, Baldini M, Aringhieri S, Fasciani I, Annibale P, Maggio R and
Scarselli M: Atypical antipsychotics and metabolic syndrome: From
molecular mechanisms to clinical differences. Pharmaceuticals
(Basel). 14:2382021. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Siafis S, Tzachanis D, Samara M and
Papazisis G: Antipsychotic drugs: From receptor-binding profiles to
metabolic side effects. Curr Neuropharmacol. 16:1210–1223. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Grajales D, Ferreira V and Valverde ÁM:
Second-Generation antipsychotics and dysregulation of glucose
metabolism: Beyond weight gain. Cells. 8:13362019. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Lis M, Stańczykiewicz B, Liśkiewicz P and
Misiak B: Impaired hormonal regulation of appetite in
schizophrenia: A narrative review dissecting intrinsic mechanisms
and the effects of antipsychotics. Psychoneuroendocrinology.
119:1047442020. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Popovic V, Doknic M, Maric N, Pekic S,
Damjanovic A, Miljic D, Popovic S, Miljic N, Djurovic M,
Jasovic-Gasic M, et al: Changes in neuroendocrine and metabolic
hormones induced by atypical antipsychotics in normal-weight
patients with Schizophrenia. Neuroendocrinology. 85:249–256. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Venkatasubramanian G, Chittiprol S,
Neelakantachar N, Shetty T and Gangadhar BN: Effect of
antipsychotic treatment on Insulin-like Growth Factor-1 and
cortisol in schizophrenia: A longitudinal study. Schizophr Res.
119:131–137. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Smith GC, Zhang ZY, Mulvey T, Petersen N,
Lach S, Xiu P, Phillips A, Han W, Wang MW and Shepherd PR:
Clozapine directly increases insulin and glucagon secretion from
islets: Implications for impairment of glucose tolerance. Schizophr
Res. 157:128–133. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Ebdrup BH, Knop FK, Madsen A, Mortensen
HB, Søgaard B, Holst JJ, Szecsi PB and Lublin H: Glucometabolic
hormones and cardiovascular risk markers in antipsychotic-treated
patients. J Clin Psychiatry. 75:e899–e905. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Klemettilä JP, Solismaa A, Seppälä N,
Hämäläinen M, Moilanen E, Leinonen E and Kampman O: Glucagon-like
peptide-1 serum levels are associated with weight gain in patients
treated with clozapine. Psychiatry Res. 306:1142272021. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Basoglu C, Oner O, Ates AM, Algul A, Semiz
UB, Ebrinc S, Cetin M, Ozcan O and Ipcioglu OM: Association between
symptom improvement and change of body mass index, lipid profile,
and leptin, ghrelin, and cholecystokinin levels during 6-week
olanzapine treatment in patients with first-episode psychosis. J
Clin Psychopharmacol. 30:636–638. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
van der Zwaal EM, Merkestein M, Lam YK,
Brans MA, Luijendijk MC, Bok LI, Verheij ER, la Fleur SE and Adan
RA: The acute effects of olanzapine on ghrelin secretion, CCK
sensitivity, meal size, locomotor activity and body temperature.
Int J Obes (Lond). 36:254–261. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Wu TH, Chiu CC, Goh KK, Chen PY, Huang MC,
Chen CH and Lu ML: Relationship between metabolic syndrome and
acylated/desacylated ghrelin ratio in patients with schizophrenia
under olanzapine medication. J Psychopharmacol. 34:86–92. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Zhang Q, Deng C and Huang XF: The role of
ghrelin signalling in second-generation antipsychotic-induced
weight gain. Psychoneuroendocrinology. 38:2423–2438. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Goetz RL and Miller BJ: Meta-analysis of
ghrelin alterations in schizophrenia: Effects of olanzapine.
Schizophr Res. 206:21–26. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Bartoli F, Lax A, Crocamo C, Clerici M and
Carrà G: Plasma adiponectin levels in schizophrenia and role of
second-generation antipsychotics: A meta-analysis.
Psychoneuroendocrinology. 56:179–189. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Kelesidis T, Kelesidis I, Sharon C and
Mantzoros SC: Narrative review: The role of leptin in human
physiology: Emerging clinical applications. Ann Intern Med.
152:93–100. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Petrikis P, Karampas A, Leondaritis G,
Markozannes G, Archimandriti DT, Spyrou P, Georgiou G, Skapinakis P
and Voulgari PV: Adiponectin, leptin and resistin levels in
first-episode, drug-naïve patients with psychosis before and after
short-term antipsychotic treatment. J Psychosom Res.
157:1107892022. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Obradovic M, Sudar-Milovanovic E, Soskic
S, Essack M, Arya S, Stewart AJ, Gojobori T and Isenovic ER: Leptin
and obesity: Role and clinical implication. Front Endocrinol
(Lausanne). 12:5858872021. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Chen PY, Chang CK, Chen CH, Fang SC,
Mondelli V, Chiu CC, Lu ML, Hwang LL and Huang MC: Orexin-a
elevation in antipsychotic-treated compared to drug-free patients
with schizophrenia: A medication effect independent of metabolic
syndrome. J Formos Med Assoc. 121:2172–2181. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Basoglu C, Oner O, Gunes C, Semiz UB, Ates
AM, Algul A, Ebrinc S, Cetin M, Ozcan O and Ipcioglu O: Plasma
orexin A, ghrelin, cholecystokinin, visfatin, leptin and
agouti-related protein levels during 6-week olanzapine treatment in
first-episode male patients with psychosis. Int Clin
Psychopharmacol. 25:165–171. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Zhu Y, Zhang C, Siafis S, Zhuo K, Zhu D,
Wu H, Liu D, Jiang K, Wang J, Leucht S and Li C: Prolactin levels
influenced by antipsychotic drugs in schizophrenia: A systematic
review and network meta-analysis. Schizophr Res. 237:20–25. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Srisawat U, Reynolds GP, Zhang ZJ, Zhang
XR, Arranz B, San L and Dalton CF: Methylenetetrahydrofolate
reductase (MTHFR) 677C/T polymorphism is associated with
antipsychotic-induced weight gain in first-episode schizophrenia.
Int J Neuropsychopharmacol. 17:485–490. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Ellingrod VL, Miller DD, Taylor SF, Moline
J, Holman T and Kerr J: Metabolic syndrome and insulin resistance
in schizophrenia patients receiving antipsychotics genotyped for
the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C
variants. Schizophr Res. 98:47–54. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Cojocaru A, Braha A, Jeleriu R, Andreescu
NI, Puiu M, Ageu L, Folescu R, Zamfir CL and Nussbaum LA: The
implications of cytochrome P450 2D6/CYP2D6 polymorphism in the
therapeutic response of atypical antipsychotics in adolescents with
psychosis-A prospective study. Biomedicines. 12:4942024. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Bertilsson L, Dahl M, Dalén P and
Al-Shurbaji A: Molecular genetics of CYP2D6: Clinical relevance
with focus on psychotropic drugs. Br J Clin Pharmacol. 53:111–122.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Wannasuphoprasit Y, Andersen SE, Arranz
MJ, Catalan R, Jurgens G, Kloosterboer SM, Rasmussen HB, Bhat A,
Irizar H, Koller D, et al: CYP2D6 genetic variation and
antipsychotic-induced weight gain: A systematic review and
meta-analysis. Front Psychol. 12:7687482022. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Jürgens G, Kaas-Hansen BS, Nordentoft M,
Werge T and Andersen SE: Is the CYP2D6 genotype associated with
antipsychotic-induced weight gain? J Pers Med. 12:17282022.
View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Austin-Zimmerman I, Wronska M, Wang B,
Irizar H, Thygesen JH, Bhat A, Denaxas S, Fatemifar G, Finan C,
Harju-Seppänen J, et al: The Influence of CYP2D6 and CYP2C19
genetic variation on diabetes mellitus risk in people taking
antidepressants and antipsychotics. Genes (Basel). 12:17582021.
View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Melkersson KI, Scordo MG, Gunes A and Dahl
ML: Impact of CYP1A2 and CYP2D6 Polymorphisms on drug metabolism
and on insulin and lipid elevations and insulin resistance in
clozapine-treated patients. J Clin Psychiatry. 68:697–704. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Hasan A, Falkai P, Wobrock T, Lieberman J,
Glenthoj B, Gattaz WF, Thibaut F and Möller HJ; WFSBP Task force on
Treatment Guidelines for Schizophrenia, : World federation of
societies of biological psychiatry (WFSBP) guidelines for
biological treatment of Schizophrenia, Part 2: Update 2012 on the
long-term treatment of schizophrenia and management of
antipsychotic-induced side effects. World J Biol Psychiatry.
14:2–44. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Dombrowski SU, Avenell A and Sniehott FF:
Behavioural interventions for obese adults with additional risk
factors for morbidity: Systematic review of effects on behaviour,
weight and disease risk factors. Obes Facts. 3:377–396. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Bruins J, Jörg F, Bruggeman R, Slooff C,
Corpeleijn E and Pijnenborg M: The effects of lifestyle
interventions on (Long-Term) weight management, cardiometabolic
risk and depressive symptoms in people with psychotic disorders: A
meta-analysis. PLoS One. 9:e1122762014. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Caemmerer J, Correll CU and Maayan L:
Acute and maintenance effects of non-pharmacologic interventions
for antipsychotic associated weight gain and metabolic
abnormalities: A meta-analytic comparison of randomized controlled
trials. Schizophr Res. 140:159–168. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Bartels SJ, Pratt SI, Aschbrenner KA,
Barre LK, Naslund JA, Wolfe R, Xie H, McHugo GJ, Jimenez DE, Jue K,
et al: Pragmatic replication trial of health promotion coaching for
obesity in serious mental illness and maintenance of outcomes. Am J
Psychiatry. 172:344–352. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Daumit GL, Goldberg RW, Anthony C,
Dickerson F, Brown CH, Kreyenbuhl J, Wohlheiter K and Dixon LB:
Physical activity patterns in adults with severe mental illness. J
Nerv Ment Dis. 193:641–646. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Cristiano VB, Szortyka MF and
Belmonte-de-Abreu P: A controlled open clinical trial of the
positive effect of a physical intervention on quality of life in
schizophrenia. Front Psychiatry. 14:10665412023. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Álvarez-Jiménez M, González-Blanch C,
Vázquez-Barquero JL, Pérez-Iglesias R, Martínez-García O,
Pérez-Pardal T, Ramírez-Bonilla ML and Crespo-Facorro B:
Attenuation of antipsychotic-induced weight gain with early
behavioral intervention in drug-naive first-episode psychosis
patients: A randomized controlled trial. J Clin Psychiatry.
67:1253–1260. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Curtis J, Watkins A, Rosenbaum S, Teasdale
S, Kalucy M, Samaras K and Ward PB: Evaluating an individualized
lifestyle and life skills intervention to prevent
antipsychotic-induced weight gain in first-episode psychosis. Early
Interv Psychiatry. 10:267–276. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Tang M, Zhao T, Liu T, Dang R, Cai H and
Wang Y: Nutrition and schizophrenia: Associations worthy of
continued revaluation. Nutr Neurosci. 27:528–546. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Adamowicz K, Mazur A, Mak M, Samochowiec J
and Kucharska-Mazur J: Metabolic syndrome and cognitive functions
in schizophrenia-implementation of dietary intervention. Front
Psychiatry. 11:3592020. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Włodarczyk A, Wiglusz MS and Cubała WJ:
Ketogenic diet for schizophrenia: Nutritional approach to
antipsychotic treatment. Med Hypotheses. 118:74–77. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Hassan N, Dumlao N, Tran K and Zamiri A:
Improving quality of life with nutritional supplementation in
Schizophrenia: A literature review. Eur Psychiatry. 65 (Suppl
1):S5952022. View Article : Google Scholar
|
|
159
|
Fernández-Abascal B, Suarez-Pinilla M,
Cobo-Corrales C, Crespo-Facorro B and Suárez-Pinilla P: Lifestyle
intervention on psychotherapy and exercise and their effect on
physical and psychological health in outpatients with schizophrenia
spectrum disorders. A pragmatic clinical trial. Eur Psychiatry. 65
(Suppl 1):S130–S131. 2022. View Article : Google Scholar
|
|
160
|
Agarwal SM, Panda R, Costa-Dookhan KA,
MacKenzie NE, Treen QC, Caravaggio F, Hashim E, Leung G, Kirpalani
A, Matheson K, et al: Metformin for early comorbid glucose
dysregulation and schizophrenia spectrum disorders: A pilot
double-blind randomized clinical trial. Transl Psychiatry.
11:2192021. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Jarskog LF, Hamer RM, Catellier DJ,
Stewart DD, Lavange L, Ray N, Golden LH, Lieberman JA and Stroup
TS; METS Investigators, : Metformin for weight loss and metabolic
control in overweight outpatients with schizophrenia and
schizoaffective disorder. Am J Psychiatry. 170:1032–1040. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
162
|
de Silva VA, Suraweera C, Ratnatunga SS,
Dayabandara M, Wanniarachchi N and Hanwella R: Metformin in
prevention and treatment of antipsychotic induced weight gain: A
systematic review and meta-analysis. BMC Psychiatry. 16:3412016.
View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Wu RR, Zhang FY, Gao KM, Ou JJ, Shao P,
Jin H, Guo WB, Chan PK and Zhao JP: Metformin treatment of
antipsychotic-induced dyslipidemia: An analysis of two randomized,
placebo-controlled trials. Mol Psychiatry. 21:1537–1544. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Battini V, Cirnigliaro G, Leuzzi R,
Rissotto E, Mosini G, Benatti B, Pozzi M, Nobile M, Radice S,
Carnovale C, et al: The potential effect of metformin on cognitive
and other symptom dimensions in patients with schizophrenia and
antipsychotic-induced weight gain: A systematic review,
meta-analysis, and meta-regression. Front Psychiatry.
14:12158072023. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Rena G, Hardie DG and Pearson ER: The
mechanisms of action of metformin. Diabetologia. 60:1577–1585.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Bu Y, Peng M, Tang X, Xu X, Wu Y, Chen AF
and Yang X: Protective effects of metformin in various
cardiovascular diseases: Clinical evidence and AMPK-dependent
mechanisms. J Cell Mol Med. 26:4886–4903. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Shah M and Vella A: Effects of GLP-1 on
appetite and weight. Rev Endocr Metab Disord. 15:181–187. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Müller TD, Finan B, Bloom SR, D'Alessio D,
Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF,
et al: Glucagon-like peptide 1 (GLP-1). Mol Metab. 30:72–130. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Sattar N, Lee MMY, Kristensen SL, Branch
KRH, Del Prato S, Khurmi NS, Lam CSP, Lopes RD, McMurray JJV,
Pratley RE, et al: Cardiovascular, mortality, and kidney outcomes
with GLP-1 receptor agonists in patients with type 2 diabetes: A
systematic review and meta-analysis of randomised trials. Lancet
Diabetes Endocrinol. 9:653–662. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Medak KD, Shamshoum H, Peppler WT and
Wright DC: GLP1 receptor agonism protects against acute
olanzapine-induced hyperglycemia. Am J Physiol Endocrinol Metab.
319:E1101–E1111. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Larsen JR, Vedtofte L, Jakobsen MSL,
Jespersen HR, Jakobsen MI, Svensson CK, Koyuncu K, Schjerning O,
Oturai PS, Kjaer A, et al: Effect of liraglutide treatment on
prediabetes and overweight or obesity in clozapine- or
olanzapine-treated patients with schizophrenia spectrum disorder.
JAMA Psychiatry. 74:719–728. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Siskind DJ, Russell AW, Gamble C, Winckel
K, Mayfield K, Hollingworth S, Hickman I, Siskind V and Kisely S:
Treatment of clozapine-associated obesity and diabetes with
exenatide in adults with schizophrenia: A randomized controlled
trial (CODEX). Diabetes Obes Metab. 20:1050–1055. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Babic I, Gorak A, Engel M, Sellers D, Else
P, Osborne AL, Pai N, Huang XF, Nealon J and Weston-Green K:
Liraglutide prevents metabolic side-effects and improves
recognition and working memory during antipsychotic treatment in
rats. J Psychopharmacol. 32:578–590. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Lykkegaard K, Larsen PJ, Vrang N, Bock C,
Bock T and Knudsen LB: The once-daily human GLP-1 analog,
liraglutide, reduces olanzapine-induced weight gain and glucose
intolerance. Schizophr Res. 103:94–103. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Whicher CA, Price HC, Phiri P, Rathod S,
Barnard-Kelly K, Ngianga K, Thorne K, Asher C, Peveler RC, McCarthy
J and Holt RIG: The use of liraglutide 3.0 mg daily in the
management of overweight and obesity in people with schizophrenia,
schizoaffective disorder and first episode psychosis: Results of a
pilot randomized, double-blind, placebo-controlled trial. Diabetes
Obes Metab. 23:1262–1271. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Perlis LT, Lamberti JS and Miedlich SU:
Glucagon-like peptide analogs are superior for diabetes and weight
control in patients on antipsychotic medications. Prim Care
Companion CNS Disord. 22:19m025042020. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Lee SE, Lee NY, Kim SH, Kim KA and Kim YS:
Effect of liraglutide 3.0mg treatment on weight reduction in obese
antipsychotic-treated patients. Psychiatry Res. 299:1138302021.
View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Siskind D, Russell A, Gamble C, Baker A,
Cosgrove P, Burton L and Kisely S: Metabolic measures 12 months
after a randomised controlled trial of treatment of clozapine
associated obesity and diabetes with exenatide (CODEX). J Psychiatr
Res. 124:9–12. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Khaity A, Mostafa Al-dardery N, Albakri K,
Abdelwahab OA, Hefnawy MT, Yousef YAS, Taha RE, Swed S, Hafez W,
Hurlemann R and Elsayed MEG: Glucagon-like peptide-1
receptor-agonists treatment for cardio-metabolic parameters in
schizophrenia patients: A systematic review and meta-analysis.
Front Psychiatry. 14:11536482023. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Ishøy PL, Knop FK, Vilsbøll T, Glenthøj BY
and Ebdrup BH: Sustained weight loss after treatment with a
glucagon-like peptide-1 receptor agonist in an obese patient with
schizophrenia and type 2 diabetes. Am J Psychiatry. 170:681–682.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Siskind D, Wysoczanski D, Russell A and
Ashford M: Weight loss associated with exenatide in an obese man
with diabetes commenced on clozapine. Aust N Z J Psychiatry.
50:702–703. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Mayfield K, Siskind D, Winckel K, Russell
AW, Kisely S, Smith G and Hollingworth S: Glucagon-like peptide-1
agonists combating clozapine-associated obesity and diabetes. J
Psychopharmacol. 30:227–236. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
del Olmo-Garcia MI and Merino-Torres JF:
GLP-1 receptor agonists and cardiovascular disease in patients with
type 2 diabetes. J Diabetes Res. 2018:40204922018. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Nauck MA, Meier JJ, Cavender MA, Abd El
Aziz M and Drucker DJ: Cardiovascular actions and clinical outcomes
with glucagon-like peptide-1 receptor agonists and dipeptidyl
peptidase-4 inhibitors. Circulation. 136:849–870. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Pelle MC, Zaffina I, Giofrè F, Pujia R and
Arturi F: Potential role of glucagon-like peptide-1 receptor
agonists in the treatment of cognitive decline and dementia in
diabetes mellitus. Int J Mol Sci. 24:113012023. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Lewitt MS and Boyd GW: Role of the
insulin-like growth factor system in neurodegenerative disease. Int
J Mol Sci. 25:45122024. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Yaribeygi H, Rashidy-Pour A, Atkin SL,
Jamialahmadi T and Sahebkar A: GLP-1 mimetics and cognition. Life
Sci. 264:1186452021. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Flintoff J, Kesby JP, Siskind D and Burne
TH: Treating cognitive impairment in schizophrenia with GLP-1RAs:
An overview of their therapeutic potential. Expert Opin Investig
Drugs. 30:877–891. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Svensson CK, Larsen JR, Vedtofte L,
Jakobsen MSL, Jespersen HR, Jakobsen MI, Koyuncu K, Schjerning O,
Nielsen J, Ekstrøm CT, et al: One-year follow-up on liraglutide
treatment for prediabetes and overweight/obesity in clozapine- or
olanzapine-treated patients. Acta Psychiatr Scand. 139:26–36. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Ganeshalingam AA, Uhrenholt NG, Arnfred S,
Gæde PH, Bilenberg N and Frystyk J: home-based intervention with
semaglutide treatment of neuroleptic-related prediabetes (HISTORI):
Protocol describing a prospective, randomised, placebo controlled
and double-blinded multicentre trial. BMJ Open. 14:e0771732024.
View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Siskind D, Baker A, Russell A, Warren N,
Robinson G, Parker S, Medland S, Kisely S, Hager T and Arnautovska
U: Effects of semaglutide on body weight in clozapine-treated
people with schizophrenia and obesity: Study protocol for a
placebo-controlled, randomised multicentre trial (COaST). BJPsych
Open. 9:e1362023. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Sass MR, Danielsen AA, Köhler-Forsberg O,
Storgaard H, Knop FK, Nielsen MØ, Sjödin AM, Mors O, Correll CU,
Ekstrøm C, et al: Effect of the GLP-1 receptor agonist semaglutide
on metabolic disturbances in clozapine-treated or
olanzapine-treated patients with a schizophrenia spectrum disorder:
Study protocol of a placebo-controlled, randomised clinical trial
(SemaPsychiatry). BMJ Open. 13:e0686522023. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Chao EC: SGLT-2 inhibitors: A new
mechanism for glycemic control. Clin Diabetes. 32:4–11. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Salvatore T, Galiero R, Caturano A,
Rinaldi L, Di Martino A, Albanese G, Di Salvo J, Epifani R,
Marfella R, Docimo G, et al: An overview of the cardiorenal
protective mechanisms of SGLT2 inhibitors. Int J Mol Sci.
23:36512022. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Vasiliu O: Impact of SGLT2 inhibitors on
metabolic status in patients with psychiatric disorders undergoing
treatment with second-generation antipsychotics (Review). Exp Ther
Med. 25:1252023. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Ashraf GM, Alghamdi BS, Alshehri FS, Alam
MZ, Tayeb HO and Tarazi FI: Empagliflozin effectively attenuates
olanzapine-induced body weight gain in female wistar rats. Front
Pharmacol. 12:5787162021. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Cernea S, Dima L, Correll CU and Manu P:
Pharmacological management of glucose dysregulation in patients
treated with second-generation antipsychotics. Drugs. 80:1763–1781.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Lally J, O' Loughlin A, Stubbs B,
Guerandel A, O'Shea D and Gaughran F: Pharmacological management of
diabetes in severe mental illness: A comprehensive clinical review
of efficacy, safety and tolerability. Expert Rev Clin Pharmacol.
11:411–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Barbosa M and Fernandes V: Rapid-onset
clozapine-induced hyperglycaemia: pathways of glycaemic
dysregulation. BMJ Case Rep. 14:e2439382021. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
National Library of Medicine, .
Empagliflozin Addition in Modulating Metabolic Disturbances
Associated With Olanzapine in Schizophrenia Patients.
Clinicaltrials.gov. https://clinicaltrials.gov/study/NCT05669742October
5–2024
|
|
201
|
Cochrane Central Register of Controlled
Trials, . Effect of Sodium Glucose Co-transporter 2 (SGLT2)
inhibitor on reducing atypical antipsychotics-induced weight gain
in schizophrenia spectrum disorder - A Randomized Controlled Trial.
https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02750108/full?highlightAbstract=inhibitors%7Cschizophreni%7Cschizophrenia%7Cinhibitor%7C*sglt2October
5–2024
|
|
202
|
Quinn CE, Hamilton PK, Lockhart CJ and
McVeigh GE: Thiazolidinediones: Effects on insulin resistance and
the cardiovascular system. Br J Pharmacol. 153:636–645. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Smith RC, Jin H, Li C, Bark N, Shekhar A,
Dwivedi S, Mortiere C, Lohr J, Hu Q and Davis JM: Effects of
pioglitazone on metabolic abnormalities, psychopathology, and
cognitive function in schizophrenic patients treated with
antipsychotic medication: A randomized double-blind study.
Schizophr Res. 143:18–24. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Edlinger M, Ebenbichler C, Rettenbacher M
and Fleischhacker WW: Treatment of antipsychotic-associated
hyperglycemia with pioglitazone. J Clin Psychopharmacol.
27:403–404. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Iranpour N, Zandifar A, Farokhnia M,
Goguol A, Yekehtaz H, Khodaie-Ardakani MR, Salehi B, Esalatmanesh
S, Zeionoddini A, Mohammadinejad P, et al: The effects of
pioglitazone adjuvant therapy on negative symptoms of patients with
chronic schizophrenia: A double-blind and placebo-controlled trial.
Hum Psychopharmacol. 31:103–112. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Yi Z, Fan X, Wang J, Liu D, Freudenreich
O, Goff D and Henderson DC: Rosiglitazone and cognitive function in
clozapine-treated patients with schizophrenia: A pilot study.
Psychiatry Res. 200:79–82. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Henderson DC, Fan X, Sharma B, Copeland
PM, Borba CP, Boxill R, Freudenreich O, Cather C, Eden Evins A and
Goff DC: A double-blind, placebo-controlled trial of rosiglitazone
for clozapine-induced glucose metabolism impairment in patients
with Schizophrenia. Acta Psychiatr Scand. 119:457–465. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Baptista T, Rangel N, El Fakih Y,
Uzcátegui E, Galeazzi T, Beaulieu S and Araujo de Baptista E:
Rosiglitazone in the assistance of metabolic control during
olanzapine administration in Schizophrenia: A pilot double-blind,
placebo-controlled, 12-week trial. Pharmacopsychiatry. 42:14–19.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Wallach JD, Wang K, Zhang AD, Cheng D,
Grossetta Nardini HK, Lin H, Bracken MB, Desai M, Krumholz HM and
Ross JS: Updating insights into rosiglitazone and cardiovascular
risk through shared data: Individual patient and summary level
meta-analyses. BMJ. 368:l70782020. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Agarwal SM and Stogios N: Cardiovascular
health in severe mental illness: Potential role for metformin. J
Clin Psychiatry. 83:22ac144192022. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Liao X, Ye H and Si T: A review of
switching strategies for patients with schizophrenia comorbid with
metabolic syndrome or metabolic abnormalities. Neuropsychiatr Dis
Treat. 17:453–469. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Mukundan A, Faulkner G, Cohn T and
Remington G: Antipsychotic switching for people with schizophrenia
who have neuroleptic-induced weight or metabolic problems. Cochrane
Database Syst Rev. 2010:CD0066292010.PubMed/NCBI
|
|
213
|
Henderson DC, Kunkel L, Nguyen DD, Borba
CP, Daley TB, Louie PM, Freudenreich O, Cather C, Evins AE and Goff
DC: An exploratory open-label trial of aripiprazole as an adjuvant
to clozapine therapy in chronic schizophrenia. Acta Psychiatr
Scand. 113:142–147. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Fleischhacker WW, Heikkinen ME, Olié JP,
Landsberg W, Dewaele P, McQuade RD, Loze JY, Hennicken D and
Kerselaers W: Effects of adjunctive treatment with aripiprazole on
body weight and clinical efficacy in schizophrenia patients treated
with clozapine: A randomized, double-blind, placebo-controlled
trial. Int J Neuropsychopharmacol. 13:1115–1125. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Henderson DC, Fan X, Copeland PM, Sharma
B, Borba CP, Boxill R, Freudenreich O, Cather C, Evins AE and Goff
DC: Aripiprazole added to overweight and obese olanzapine-treated
schizophrenia patients. J Clin Psychopharmacol. 29:165–169. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Mizuno Y, Suzuki T, Nakagawa A, Yoshida K,
Mimura M, Fleischhacker WW and Uchida H: Pharmacological strategies
to counteract antipsychotic-induced weight gain and metabolic
adverse effects in schizophrenia: A systematic review and
meta-analysis. Schizophr Bull. 40:1385–1403. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Fan X, Borba CP, Copeland P, Hayden D,
Freudenreich O, Goff DC and Henderson DC: Metabolic effects of
adjunctive aripiprazole in clozapine-treated patients with
schizophrenia. Acta Psychiatr Scand. 127:217–226. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
218
|
El Hayek SA, Shatila MA, Adnan JA, Geagea
LE, Kobeissy F and Talih FR: Is there a therapeutic potential in
combining bupropion and naltrexone in schizophrenia? Expert Rev
Neurother. 22:737–749. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
219
|
Lyu X, Du J, Zhan G, Wu Y, Su H, Zhu Y,
Jarskog F, Zhao M and Fan X: Naltrexone and bupropion combination
treatment for smoking cessation and weight loss in patients with
schizophrenia. Front Pharmacol. 9:1812018. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Naguy A and Badr BHM:
Bupropion-myth-busting! CNS Spectr. 27:545–546. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
221
|
Kumar S, Kodela S, Detweiler JG, Kim KY
and Detweiler MB: Bupropion-induced psychosis: Folklore or a fact?
A systematic review of the literature. Gen Hosp Psychiatry.
33:612–617. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
222
|
Grover S and Das PP: Can bupropion unmask
psychosis. Indian J Psychiatry. 51:53–54. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
223
|
Wang TS, Shiah IS, Yeh CB and Chang CC:
Acute psychosis following sustained release bupropion overdose.
Prog Neuropsychopharmacol Biol Psychiatry. 29:149–151. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
224
|
Deberdt W, Winokur A, Cavazzoni PA,
rzaskoma QN, Carlson CD, Bymaster FP, Wiener K, Floris M and Breier
A: Amantadine for weight gain associated with olanzapine treatment.
Eur Neuropsychopharmacol. 15:13–21. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
225
|
Graham KA, Gu H, Lieberman JA, Harp JB and
Perkins DO: Double-Blind, placebo-controlled investigation of
amantadine for weight loss in subjects who gained weight with
olanzapine. Am J Psychiatry. 162:1744–1746. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
226
|
Xu WJ, Wei N, Xu Y and Hu SH: Does
amantadine induce acute psychosis? A case report and literature
review. Neuropsychiatr Dis Treat. 12:781–783. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
227
|
Raskind MA, Burke BL, Crites NJ, Tapp AM
and Rasmussen DD: Olanzapine-induced weight gain and increased
visceral adiposity is blocked by melatonin replacement therapy in
rats. Neuropsychopharmacology. 32:284–288. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
228
|
Romo-Nava F, Alvarez-Icaza González D,
Fresán-Orellana A, Saracco Alvarez R, Becerra-Palars C, Moreno J,
Ontiveros Uribe MP, Berlanga C, Heinze G and Buijs RM: Melatonin
attenuates antipsychotic metabolic effects: an eight-week
randomized, double-blind, parallel-group, placebo-controlled
clinical trial. Bipolar Disord. 16:410–421. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
229
|
Modabbernia A, Heidari P, Soleimani R,
Sobhani A, Roshan ZA, Taslimi S, Ashrafi M and Modabbernia MJ:
Melatonin for prevention of metabolic side-effects of olanzapine in
patients with first-episode schizophrenia: Randomized double-blind
placebo-controlled study. J Psychiatr Res. 53:133–140. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
230
|
Padwal R, Kezouh A, Levine M and Etminan
M: Long-term persistence with orlistat and sibutramine in a
population-based cohort. Int J Obes (Lond). 31:1567–1570. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
231
|
Tchoukhine E, Takala P, Hakko H, Raidma M,
Putkonen H, Räsänen P, Terevnikov V, Stenberg JH, Eronen M and
Joffe G: Orlistat in clozapine- or olanzapine-treated patients with
overweight or obesity: A 16-week open-label extension phase and
both phases of a randomized controlled trial. J Clin Psychiatry.
72:326–330. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
232
|
Kramer CK, Leitão CB, Pinto LC, Canani LH,
Azevedo MJ and Gross JL: Efficacy and safety of topiramate on
weight loss: A meta-analysis of randomized controlled trials. Obes
Rev. 12:e338–47. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
233
|
Thompson PJ, Baxendale SA, Duncan JS and
Sander JW: Effects of topiramate on cognitive function. J Neurol
Neurosurg Psychiatry. 69:636–641. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
234
|
Loring DW, Williamson DJ, Meador KJ,
Wiegand F and Hulihan J: Topiramate dose effects on cognition: A
randomized double-blind study. Neurology. 76:131–137. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
235
|
Poyurovsky M, Isaacs I, Fuchs C,
Schneidman M, Faragian S, Weizman R and Weizman A: Attenuation of
olanzapine-induced weight gain with reboxetine in patients with
schizophrenia: A double-blind, placebo-controlled study. Am J
Psychiatry. 160:297–302. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
236
|
Poyurovsky M, Fuchs C, Pashinian A, Levi
A, Faragian S, Maayan R and Gil-Ad I: Attenuating effect of
reboxetine on appetite and weight gain in olanzapine-treated
schizophrenia patients: A double-blind placebo-controlled study.
Psychopharmacology (Berl). 192:441–448. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
237
|
Ghanizadeh A, Nikseresht MS and Sahraian
A: The effect of zonisamide on antipsychotic-associated weight gain
in patients with schizophrenia: A randomized, double-blind,
placebo-controlled clinical trial. Schizophr Res. 147:110–115.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
238
|
Hamoui N, Kingsbury S, Anthone GJ and
Crookes PF: Surgical treatment of morbid obesity in schizophrenic
patients. Obes Surg. 14:349–352. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
239
|
Fuchs HF, Laughter V, Harnsberger CR,
Broderick RC, Berducci M, DuCoin C, Langert J, Sandler BJ, Jacobsen
GR, Perry W and Horgan S: Patients with psychiatric comorbidity can
safely undergo bariatric surgery with equivalent success. Surg
Endosc. 30:251–258. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
240
|
Shelby SR, Labott S and Stout RA:
Bariatric surgery: A viable treatment option for patients with
severe mental illness. Surg Obes Relat Dis. 11:1342–1348. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
241
|
Ahmed AT, Warton EM, Schaefer CA, Shen L
and McIntyre RS: The effect of bariatric surgery on psychiatric
course among patients with bipolar disorder. Bipolar Disord.
15:753–763. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
242
|
D'Arcey J, Torous J, Asuncion TR,
Tackaberry-Giddens L, Zahid A, Ishak M, Foussias G and Kidd S:
Leveraging personal technologies in the treatment of schizophrenia
spectrum disorders: Scoping review. JMIR Ment Health.
11:e571502024. View
Article : Google Scholar : PubMed/NCBI
|
